Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merus N.V. - Common Shares (NQ:MRUS)

90.00 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merus N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session ↗
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60. 
Via Benzinga
News headline image
Merus Announces Financial Results for the Third Quarter and Provides Business Update
From Merus N.V.
Via GlobeNewswire
News headline image
What 4 Analyst Ratings Have To Say About Merus ↗
Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings: 
Via Benzinga
News headline image
4 Analysts Have This to Say About Merus ↗
Within the last quarter, Merus (NASDAQ:MRUS) has observed the following analyst ratings: 
Via Benzinga
News headline image
Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday ↗
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the... 
Via Benzinga
News headline image
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
From Merus N.V.
Via GlobeNewswire
News headline image
Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus ↗
Incyte Corporation (NASDAQ: INCY) is  
Via Benzinga
News headline image
Why Seagate Shares Are Trading Lower By More Than 7%? Here Are 49 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares surged 59.3% to $2.7417 after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate... 
Via Benzinga
News headline image
Albemarle To Rally Around 8%? Here Are 5 Other Price Target Changes For Thursday ↗
Berenberg raised Albemarle Corporation (NYSE: ALB) price target from $260 to $270. Berenberg analyst Andres Castanos Mollor downgraded the stock from Buy to Hold. Albemarle shares fell 7.9% to close at... 
Via Benzinga
News headline image
Analyst Casts Doubts On Merus' Lung Candidate Safety Profile ↗
Earlier today, Merus N.V. (NASDAQ: MRUS) announced the publication of the abstract highlighting interim data from the ongoing phase 1/2 trial of the bispecific antibody MCLA-129 in advanced non-small... 
Via Benzinga
News headline image
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
From Merus N.V.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Merus Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Thursday, Netherlands-based Merus stock had its Relative Strength (RS) Rating upgraded to 94 from 78 a day earlier. 
Via Investor's Business Daily
News headline image
Needham Says Merus' ASCO Update On Zeno 'Positive' ↗
Needham writes that Merus NV (NASDAQ: MRUS) has enough data to initiate an FDA marketing application filing in mid-2022 after presenting Zenocutuzumab (Zeno) data in NRG1-fusion (NRG1+) Cancer. 
Via Benzinga
News headline image
70 Biggest Movers From Friday ↗
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for... 
Via Benzinga
News headline image
7 Top-Rated Biotech Stocks to Buy for Q2 ↗
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2022 ↗
Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter,... 
Via Benzinga
Promising Developments in Breast Cancer Treatments Ahead in 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against... 
Via FinancialNewsMedia
News headline image
Merus Shares Updated Data From Zeno Triplet Combo Data In Breast Cancer Settings ↗
Merus NV (NASDAQ: MRUS) has presented updated data on zenocutuzumab (Zeno) combined with trastuzumab and vinorelbine in HER2 positive/amplified (HER2+) metastatic... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
News headline image
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... 
Via Benzinga
News headline image
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
News headline image
Notable Merus Insider Makes $31M Sale ↗
Mark Lampert, 10% Owner at Merus (NASDAQ:MRUS), made a large insider sell on October 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and... 
Via Benzinga
Topics Regulatory Compliance
News headline image
45 Biggest Movers From Yesterday ↗
Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Crude Oil Rises 1%; New Fortress Energy Shares Spike Higher ↗
Toward the end of trading Thursday, the Dow traded up 1.29% to 34,860.01 while the NASDAQ rose 1.47% to 14,714.54. The S&P also rose, gaining 1.22% to 4,416.63. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
Merus Stock Flirts With Breakout After Experimental Drug Shrinks All Tumors ↗
Merus is flirting with a buy point on its strong, early-stage cancer test results. 
Via Investor's Business Daily
News headline image
Mid-Day Market Update: Dow Jumps Over 500 Points; Osmotica Pharmaceuticals Shares Slide ↗
Midway through trading Thursday, the Dow traded up 1.51% to 34,938.25 while the NASDAQ rose 1.64% to 14,739.43. The S&P also rose, gaining 1.41% to 4,425.22. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
Here's Why Merus Stock Is Flying Higher Today ↗
This biotech's second experimental cancer drug to begin clinical trials produced some encouraging results. 
Via The Motley Fool
News headline image
Why Are Merus Shares Soaring Thursday? ↗
Merus N.V. (NASDAQ: MRUS) has presented data on MCLA-158 and preclinical data on zenocutuzumab (Zeno) at the AACR-NCI-EORTC Virtual International Conference on... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Open Higher; Conagra Brands Profit Beats Views ↗
Following the market opening Thursday, the Dow traded up 1.51% to 34,936.37 while the NASDAQ rose 1.56% to 14,728.21. The S&P also rose, gaining 1.45% to 4,426.68. The U.S.... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.